This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
MDS
Madrid
2022
Symposium

Date and time:

16.09.22 at 13:30-14:30 CET

Type:

Congress:
Speakers:

Watch the summary video from Adolfo Ramirez-Zamora for a brief synopsis of the presentation given at the live Symposium. 

Watch the summary video from Roger Barker for a brief synopsis of the presentation given at the live Symposium. 

Watch the summary video from Thomas Foltynie for a brief synopsis of the presentation given at the live Symposium. 

Welcome and introduction

How far have we come? A summary of the current treatment landscape in PD

Where do we go from here? Unmet needs in the treatment of PD and the search for disease‑modifying therapies

Dopamine cell therapies. What is the big deal?

Spotlight on emerging potential treatments for PD and implications for patients

Summary and conclusion

Adolfo Ramirez-Zamora

Adolfo Ramirez-Zamora

University of Florida, Gainesville, USA


Dr. Adolfo Ramirez-Zamora is a Professor of Neurology, Program Director and Division Chief of Movement Disorders at the Norman Fixel Institute for Neurological Diseases at the University of Florida. Prior to joining the University of Florida, Dr. Ramirez served as an Associated Professor of Neurology and the Philly E. Dake endowed Chair in Movement Disorders at the Parkinson’s Disease and Movement Disorders Center at Albany Medical Center. He completed his neurology residency at Loyola University Chicago under Dr. Jose Biller followed by fellowship training in movement disorders at the University of California San Francisco. Dr. Ramirez’s unique areas of expertise encompass the management of the entire spectrum of movement disorders, cerebellar ataxias and the use of advanced therapeutic techniques including botulinum toxin injections, deep brain stimulation (DBS) and infusion therapies for the treatment of movement disorders.

 

His research interests include exploring neurophysiological brain changes observed in these conditions, investigating new biomarkers and non-motor symptoms in Parkinson's disease, and testing novel neuromodulation techniques in the field of movement disorders. He is interested in developing and assessing evolving experimental therapeutics and clinical trials in movement disorders. Dr. Ramirez serves on the leadership of the Parkinson’s Foundation and the Parkinson Study Group. He served as a member of the Diversity leadership program and Science Committee at the American Academy of Neurology (AAN).


Read full bio
Thomas Foltynie

Thomas Foltynie

University College London (UCL), London, UK


Professor of Neurology in the Department of Clinical and Movement Neurosciences, University College London (UCL) Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

 

Professor Foltynie is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as deep brain stimulation (DBS), apomorphine and duodopa. He is chief investigator for a series of trials of exenatide – a potential neurorestorative treatment for PD, and has been UCL’s principal investigator for multi-centre trials of gene therapy and cell therapy as potential neurorestorative approaches for PD. He is the chief investigator for the Edmond J Safra Accelerating Clinical Trials in PD project, which will establish a platform for the testing of multiple potential neuroprotective approaches simultaneously in the UK.

 

Professor Foltynie has published clinical trials of DBS as a treatment for the cognitive problems associated with advanced PD/dementia with Lewy bodies (DLB), as well as successful results of a trial of DBS for the treatment of patients with severe Tourette syndrome.  He is interested in the mechanisms of action of DBS as elucidated using functional MRI and developing ways of providing therapeutic DBS with better benefit to side effect ratios.

 

He trained in medicine at UCL, qualifying in 1995 then working in Addenbrooke's Hospital in Cambridge. From 1999 to 2003, he undertook his PhD in Cambridge looking at the heterogeneity of PD, describing differences in cognitive abilities between patients under the influence of various genes including COMT and BDNF, and Tau. He finished his neurology training between Addenbrooke's Hospital, Cambridge and the National Hospital for Neurology and Neurosurgery in London, before taking up his consultant clinical academic position in London in 2008. He was promoted to Professor in 2016.


Read full bio